Archiv
Dgap-Ad hoc: Qiagen N.V. deutsch

Qiagen gibt Preisfestsetzung der US$ 150 Mio. 1,5% Wandelschuldverschreibung (En

Qiagen gibt Preisfestsetzung der US$ 150 Mio. 1,5% Wandelschuldverschreibung (En

Ad-hoc-Mitteilung übermittelt durch die Dgap. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. --------------------------------------------------------------------------------

Qiagen gibt Preisfestsetzung der US$ 150 Mio. 1,5% Wandelschuldverschreibung (Endfälligkeit 2024) bekannt

Venlo, Niederlande, 4. August 2004 - Die Qiagen N.V. (Nasdaq: Qgenf; Frankfurt, Prime Standard: QIA) meldet heute die Preisfestsetzung der nicht nachrangigen Wandelschuldverschreibungen (senior unsubordinated convertible notes) über US$ 150 Mio. mit einer Endfälligkeit im Jahr 2024, die an institutionelle Anleger außerhalb der USA auf der Grundlage der Regulation S des US Securities Act von 1933, in der jeweils maßgeblichen Fassung, verkauft wurden.

Die Wandelschuldverschreibungen können, vorbehaltlich späterer Anpassungen, zum anfänglichen Wandlungspreis von ungefähr US$ 12,6449 pro Aktie (ungefähr Euro 10,53 je Aktie) gewandelt werden. Die Wandelschuldverschreibung werden mit einem Zinskupon von 1,5% ausgestattet. Die Zinsen sind halbjährig, jeweils nachträglich zahlbar. Der Kurs der Stammaktien der Gesellschaft bei der Preisfeststellung der Wandelschuldverschreibung am 4. August 2004 um ca. 13:00 MEZ betrug ungefähr Euro 7,15 (umgerechnet ungefähr US$ 8,59).

Durch die Begebung der Wandelschuldverschreibung hat Qiagen die derzeit attraktiven Finanzierungsmöglichkeiten, die der Markt für Wandelschuldverschreibungen bietet, genutzt. Die Gesellschaft hält die Bedingungen der angebotenen Wandelschuldverschreibung gegenüber den Bedingungen ihrer gegenwärtigen Finanzierungsinstrumente für sehr vorteilhaft. Die Gesellschaft beabsichtigt, die Erlöse aus der Begebung der Wandelschuldverschreibungen zur Optimierung ihrer Bilanzstruktur, zur Rückzahlung von Verbindlichkeiten und zur Finanzierung allgemeiner gesellschaftlicher Zwecke und Akquisitionsvorhaben zu verwenden.

Die Wandelschuldverschreibungen werden durch eine 100%ige Tochtergesellschaft der Qiagen ausgegeben und durch eine Garantie seitens Qiagen abgesichert. Der Ausgabetag der Wandelschuldverschreibungen wird voraussichtlich der 18. August 2004 sein. Eine Börsennotierung der Wandelschuldverschreibungen an der Luxemburger Börse wird beantragt.

Goldman Sachs International betreut die Transaktion als einziger Bookrunner und Lead Manager.

This announcement is for general information only and does not form part of any offer to sell, or the solicitation of any offer to buy, securities. The distribution of this announcement and the offer and sale of the securities described in this announcement (the "Securities") in certain jurisdictions may be restricted by law. Any persons reading this announcement should inform themselves of and observe any such restrictions. This announcement may not be taken or transmitted in any form into the United States, Canada or Japan. This announcement is directed only at the following persons in the United Kingdom: persons having professional experience in matters relating to investments; and persons falling within Articles 49(2)(a) to (d) of the U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (high net worth corporations, unincorporated associations etc.). If you are in the United Kingdom and do not fall into one of the above categories, any investment or investment activity to which this announcement relates is not available to you, and will not be engaged in with you, and you should not act upon, or rely on, this announcement. This announcement is not an offer of securities for sale in the United States. The offer and sale of the Securities has not been, nor will it be, registered under the United States Securities Act of 1933 and the Securities may not be offered or sold in the United States absent such registration or an applicable exemption from registration. Any public offering of the Securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer or the selling security holder and that will contain detailed information about the issuer and its management, as well as financial statements. Goldman Sachs has prepared this communication based upon information that it believes to be reliable. However, Goldman Sachs does not represent or warrant that the information in this announcement is accurate, complete or up to date and accepts no liability if it is not. In connection with the offer and sale of the Securities Goldman Sachs may for its own account enter into asset swaps, credit derivatives or other derivative transactions relating to the Securities and/or the underlying shares at the same time as the offer and sale of the Securities or in secondary market transactions. Goldman Sachs may hold long or short positions in the Securities, the underlying shares or derivatives thereof. No disclosure will be made of any such positions. Stabilisation/FSA

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to Qiagen's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for Qiagen's, products (including seasonal fluctuations), difficulties in successfully adapting Qiagen's products to integrated solutions and producing such products, the ability of Qiagen to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that Qiagen has filed with the U.S. Securities and Exchange Commission (SEC)

The Notes and (the rights to subscribe for) our common stock are not and will not be offered, as part of their initial distribution or at any time thereafter, to persons who are established, domiciled or resident ("are resident") in the Netherlands other than to persons who trade or invest in securities in the conduct of their profession or trade (which includes banks, securities intermediaries (including dealers and brokers), insurance companies, pension funds, other institutional investors and commercial enterprises which as an ancillary activity regularly invest in securities). The offer of the Notes and (the rights to subscribe for) our common stock, each announcement thereof and the prospectus that will be made available comply with the laws and regulations of each State where persons to whom the offer is made are resident.

Contact: IR Qiagen N.V.; phone +49 2103 29 11710; fax +49 2103 29 21710; email ir@qiagen.com

Ende der Ad-hoc-Mitteilung (c)Dgap 04.08.2004 -------------------------------------------------------------------------------- WKN: 901626; Isin: Nl0000240000; Index: Tecdax, Nemax 50 Notiert: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart

Serviceangebote
Zur Startseite
-0%1%2%3%4%5%6%7%8%9%10%11%12%13%14%15%16%17%18%19%20%21%22%23%24%25%26%27%28%29%30%31%32%33%34%35%36%37%38%39%40%41%42%43%44%45%46%47%48%49%50%51%52%53%54%55%56%57%58%59%60%61%62%63%64%65%66%67%68%69%70%71%72%73%74%75%76%77%78%79%80%81%82%83%84%85%86%87%88%89%90%91%92%93%94%95%96%97%98%99%100%